ClinicalTrials.gg
RecruitingNCT06731907Updated Oct 16, 2026

A Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-3475-01G/KEYMAKER U01)

A Phase 2 interventional study of Pembrolizumab and Carboplatin in Non-small Cell Lung Cancer, sponsored by Merck Sharp & Dohme LLC. Recruiting at 41 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-16.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 7 months later.
Updated Oct 16, 2026Site recruiting status changed3 sites added+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 91 studies in Carcinoma, Non-Small-Cell Lung by Merck & Co., Inc — 14 open to participants now, 26 under way, 18 of them phase 3. Carcinoma, Non-Small-Cell Lung · Merck & Co., Inc.

Planned enrollment
57th of 88
90 · median 149
Started
2025
with 4 others
Phase 2
24 of 91
2 open now
Primary completion
2032-03
later than 19 of 25 live
Registered
84th of 91
by date

Among the 91 studies in Carcinoma, Non-Small-Cell Lung by Merck & Co., Inc, this one is the 57th largest by planned enrollment of the 88 interventional ones that give a count, is one of 5 that started in 2025, is one of 24 in phase 2, reaches primary completion later than 19 of the 25 other live ones, and was the 84th registered.

Carcinoma, Non-Small-Cell Lung

7,628 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

14 of the 91 studies in Carcinoma, Non-Small-Cell Lung by Merck & Co., Inc are open now, in 12 countries. Recruiting first, the newest first:

8 more — sign in →

By country, each count listing its studies:

All 14 open studies →

Who these studies take

Of the 1,325 Carcinoma, Non-Small-Cell Lung studies recruiting now, 988 (75%) set no upper age limit and 224 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 91 studies in Carcinoma, Non-Small-Cell Lung by Merck & Co., Inc, or all of them as a file.
02

Study summary

Researchers are investigating new treatments for untreated advanced non-small cell lung cancer (NSCLC), which is the most common form of lung cancer and lung cancer that has spread beyond surgical removal. Standard treatments include immunotherapy, such as pembrolizumab, and chemotherapy. This study aims to determine the effectiveness of adding other treatments, including the human epidermal growth factor receptor 3-directed antibody-drug conjugate (HER3-DXd) patritumab deruxtecan, to pembrolizumab, with or without chemotherapy. The primary goals are to assess safety and efficacy of the treatments.

03

Conditions studied

  • Non-small Cell Lung Cancer

Keywords

  • Lung Neoplasms
  • Lung Cancer
  • Pulmonary Neoplasms
  • Pulmonary Cancer
  • Non-Small Cell Lung Carcinoma
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The main inclusion criteria include but are not limited to the following:

  • or cytologically confirmed diagnosis of Stage IV squamous or non-squamous non-small cell lung cancer (NSCLC) per American Joint Committee on Cancer (AJCC) Staging Manual Version 8.
  • Has an (ECOG) performance status of either 0 or 1 as assessed within 7 days before randomization.
  • Has sample or newly obtained core, incisional, or excisional biopsy of a tumor lesion not previously irradiated has been provided.
  • (HIV)-infected participants must have well controlled HIV on ART.
  • Participants who are surface antigen (HBsAg) positive are eligible if they have received hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV viral load prior to treatment randomization.

Exclusion criteria

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following:

  • Has a diagnosis of small cell lung cancer or, for mixed tumors, presence of small cell elements.
  • Participants with squamous histology are excluded if there is a known tumor-activating epidermal growth factor receptor (EGFR) mutation or anaplastic lymphoma kinase (ALK) or c ros oncogene 1 (ROS1) gene rearrangement.
  • Is -infected with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease
  • Clinically severe pulmonary compromise resulting from intercurrent pulmonary illnesses including, but not limited to, any underlying pulmonary disorder, or any , connective tissue, or inflammatory disorders with pulmonary involvement.
  • Has evidence of any .
  • Has known history of, or active, neurologic paraneoplastic syndrome.
  • Has corneal disease.
  • Has myocardial infarction within 6 months.
  • Has (NYHA) Classes 3 or 4 congestive heart failure.
  • Has uncontrolled angina pectoris within 6 months.
  • Has cardiac arrhythmia requiring ongoing antiarrhythmic treatment.
  • Has history of clinically relevant ventricular arrhythmias, such as ventricular tachycardia, ventricular fibrillation, or Torsade de Pointes.
  • Has bradycardia of less than 50 beats per minute (bpm) unless the participant has a pacemaker.
  • Has history of second- or third-degree heart block. Candidates with a history of heart block may be eligible if they currently have pacemakers and have no history of fainting or clinically relevant arrhythmia with pacemakers.
  • Has coronary/peripheral artery bypass graft within 6 months.
  • Has complete left bundle branch block.
  • Has inadequate from prior concomitant therapy as specified in protocol before randomization.
  • Has received prior treatment with a topoisomerase I inhibitor or an anti-HER3 antibody and/or ADC that consists of an exatecan derivative that is a topoisomerase I inhibitor.
  • Has received prior systemic anticancer therapy for their NSCLC.
  • Has received prior therapy with an anti- programmed cell death 1 protein (), anti- programmed cell death ligand 1 protein (anti-PD-L1), or anti- programmed cell death ligand 2 protein (anti-PD-L2) agent, or with an agent directed to another stimulatory or coinhibitory T-cell receptor.
  • Has received prior radiotherapy within 2 weeks of randomization, has radiation related toxicity requiring , or has had radiation pneumonitis.
  • Has received radiation therapy to the lung that is >30 gray within 6 months of start of study intervention.
  • Has received a live or within 30 days before the first dose of study intervention.
  • Has diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy or any other form of therapy within 7 days prior to the first dose of study intervention.
  • Has known additional that is progressing or has required active treatment within the past 3 years.
  • Has known active central nervous system (CNS) metastases and/or carcinomatous meningitis.
  • Has severe to any of the study interventions and/or any of their .
  • Has active autoimmune disease that has required systemic treatment in the past 2 years.
  • Has active infection requiring systemic therapy.
  • Has concurrent active and virus infection.
  • Have not adequately recovered from major surgery or have ongoing surgical complications.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
90 participants (estimated)

Study arms

  • Active comparator
    Pembrolizumab and Chemotherapy

    Pembrolizumab will be administered as a 200mg IV infusion on Day 1 of every three weeks (Q3W) for up to 35 cycles (\~ 2 years). The doublet platinum-based chemotherapy treatments used in this substudy are standard-of care regimens for squamous (paclitaxel/Nab-paclitaxel and carboplatin) and nonsquamous (pemetrexed and carboplatin) NSCLC. Pemetrexed is administered as a 500mg/m\^2 IV infusion Q3W until discontinuation criterion is met. Nab-paclitaxel will be administered as a 100mg/m\^2 IV infusion on Days 1, 8, and 15 Q3W for up to 4 cycles. Paclitaxel will be administered as a 200 mg/m\^2 IV infusion on Day 1 Q3W for up to 4 cycles. Carboplatin will be administered as an IV infusion area under the time x concentration curve (AUC) for 4 cycles as per local practice and labels. The dose will be AUC5 or 6 mg/mL•min Q3W and will not exceed 900mg.

    Biological: Pembrolizumab · Drug: Carboplatin · Drug: Paclitaxel · Drug: Nab-paclitaxel · Drug: Pemetrexed

  • Experimental
    Pembrolizumab and HER3-DXd

    Pembrolizumab will be administered as a 200mg IV infusion on Day 1 Q3W for up to 35 cycles (\~ 2 years). HER3-Dxd will be administered as 5.6mg/kg IV infusion on Day 1 Q3W until discontinuation criteria is met.

    Biological: Pembrolizumab · Biological: HER3-DXd

Interventions

  • BiologicalPembrolizumab

    Pembrolizumab 200mg IV Infusion.

    Also known as: Keytruda®, MK-3475, SCH 900475

  • Carboplatin IV infusion AUC5 or 6 mg/mL•min and not exceeding 900mg.

    Also known as: Paraplatin®

  • Paclitaxel 200 mg/m\^2 IV infusion.

    Also known as: Taxol

  • Nab-paclitaxel 100mg/m\^2 IV infusion.

    Also known as: Abraxane

  • Pemetrexed 500mg/m\^2 IV infusion.

    Also known as: Alimta

  • BiologicalHER3-DXd

    HER3-Dxd 5.6mg/kg IV infusion.

    Also known as: patritumab deruxtecan, U3-1402, MK-1022

06

What researchers measure

Primary outcomes

  1. Overall Response Rate (ORR)

    ORR is defined as a confirmed complete response or partial response per Response Evaluation Criteria in Solid Tumors (RECIST) 1.1 as assessed by Blinded Independent Central Review (BICR).

    Time frame: Up to ~ 5 years

  2. Number of Participants with Adverse Events (AEs)

    Adverse events are any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research.

    Time frame: Up to ~ 5 years

  3. Number of Participants Discontinuing Study Drug Due to AEs

    Any untoward or unfavorable medical occurrence in a participant, including any abnormal sign (for example, abnormal physical exam or laboratory finding), symptom, or disease, temporally associated with the participant's participation in the research, whether or not considered related to the participant's participation in the research.

    Time frame: Up to ~ 2 years

Secondary outcomes

  1. Duration of Response (DOR)

    For participants who demonstrate a confirmed complete response (CR) or partial response (PR) per RECIST 1.1 as assessed by BICR, DOR is defined as the time from the first documented evidence of CR or PR until disease progression or death due to any cause, whichever occurs first.

    Time frame: Up to ~ 5 years

  2. Progression-free Survival (PFS)

    PFS is defined as the time from randomization to the first documented disease progression per RECIST 1.1 as assessed by BICR or death due to any cause, whichever occurs first.

    Time frame: Up to ~ 5 years

  3. Overall Survival (OS)

    OS is defined as the time from randomization to death due to any cause.

    Time frame: Up to ~ 5 years

07

Study locations

37 of 41 sites recruiting
  • University of Kentucky ( Site 0019)
    Lexington, Kentucky 40536, United States
    Recruiting
    • Study Coordinator · Contact859-218-0131
  • MedStar Franklin Square Medical Center ( Site 0033)
    Baltimore, Maryland 21237, United States
    Recruiting
    • Study Coordinator · Contact443-777-7147
  • Sanford Fargo Medical Center ( Site 0039)
    Fargo, North Dakota 58102, United States
    Recruiting
    • Study Coordinator · Contact701-234-2000
  • Abramson Cancer Center ( Site 0010)
    Philadelphia, Pennsylvania 19104, United States
    Recruiting
    • Study Coordinator · Contact215-220-9703
  • Sanford Cancer Center ( Site 0038)
    Sioux Falls, South Dakota 57104, United States
    Recruiting
    • Study Coordinator · Contact605-838-8631
  • Centro de Estudios Clínicos SAGA ( Site 0162)
    Santiago, Region M. de Santiago 7500653, Chile
    Recruiting
    • Study Coordinator · Contact991612199
  • Fundación Arturo López Pérez ( Site 0161)
    Santiago, Region M. de Santiago 7500921, Chile
    Recruiting
    • Study Coordinator · Contact981369487
  • Bradfordhill ( Site 0160)
    Santiago, Region M. de Santiago 8420383, Chile
    Recruiting
    • Study Coordinator · Contact998744662
  • THORACIC GENERAL HOSPITAL OF ATHENS "I SOTIRIA"-3rd Dept of Internal Medicine and Laboratory, Oncol ( Site 0204)
    Athens, Attica 115 27, Greece
    Recruiting
    • Study Coordinator · Contact0030 2107700220
  • European Interbalkan Medical Center-Oncology Department ( Site 0205)
    Thessaloniki, 570 01, Greece
    Recruiting
    • Study Coordinator · Contact0030 2310400213
  • Petz Aladar Egyetemi Oktato Korhaz ( Site 0062)
    Győr, Győr-Moson-Sopron 9024, Hungary
    Recruiting
    • Study Coordinator · Contact+3696507900
  • Jasz-Nagykun-Szolnok Varmegyei Hetenyi Geza Korhaz-Rendelointezet ( Site 0061)
    Szolnok, Jász-Nagykun-Szolnok 5000, Hungary
    Recruiting
    • Study Coordinator · Contact+3656503603
  • Országos Korányi Pulmonológiai Intézet ( Site 0060)
    Budapest, 1121, Hungary
    Recruiting
    • Study Coordinator · Contact+3613913200
  • Rambam Health Care Campus ( Site 0076)
    Haifa, 3109601, Israel
    Recruiting
    • Study Coordinator · Contact+972 47776234
  • Shaare Zedek Medical Center ( Site 0075)
    Jerusalem, 9103102, Israel
    Recruiting
    • Study Coordinator · Contact+972-2-6555768
  • Meir Medical Center ( Site 0071)
    Kfar Saba, 4428164, Israel
    Recruiting
    • Study Coordinator · Contact+97297472414
  • Rabin Medical Center ( Site 0074)
    Petah Tikva, 4941492, Israel
    Recruiting
    • Study Coordinator · Contact+97239378101
  • Sheba Medical Center ( Site 0070)
    Ramat Gan, 5262000, Israel
    Recruiting
    • Study Coordinator · Contact+97235307096
  • Sourasky Medical Center ( Site 0077)
    Tel Aviv, 6423906, Israel
    Recruiting
    • Study Coordinator · Contact+972-3-6973082
  • Fondazione IRCCS Istituto Nazionale dei Tumori ( Site 0175)
    Milan, Lombardy 20133, Italy
    Recruiting
    • Study Coordinator · Contact390223902190
  • IRCCS Ospedale San Raffaele ( Site 0171)
    Milan, 20132, Italy
    Recruiting
    • Study Coordinator · Contact+390223903829
  • Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Università Cattolica del Sacro Cuore ( Site 0174)
    Roma, 00168, Italy
    Recruiting
    • Study Coordinator · Contact+390630156318
  • Wielkopolskie Centrum Pulmonologii i Torakochirurgii-Oddzial Onkologii Klinicznej z Pododdzialem Dz ( Site 0153)
    Poznan, Greater Poland Voivodeship 60-569, Poland
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie ( Site 0151)
    Warsaw, Masovian Voivodeship 02-781, Poland
    Recruiting
    • Study Coordinator · Contact48225463066
  • Uniwersyteckie Centrum Kliniczne-Early Clinical Trials Unit ( Site 0150)
    Gdansk, Pomeranian Voivodeship 80-214, Poland
    Recruiting
    • Study Coordinator · Contact+48585844466
  • Szpital Wojewódzki im. Mikoaja Kopernika w Koszalinie-Oddzial Dzienny Chemioterapii ( Site 0152)
    Koszalin, West Pomeranian Voivodeship 75-581, Poland
    Recruiting
    • Study Coordinator · Contact+48502204953
  • Institut Català d'Oncologia - L'Hospitalet ( Site 0090)
    L'Hospitalet de Llobregat, Barcelona 08908, Spain
    Recruiting
    • Study Coordinator · Contact0034932607744
  • Hospital Clinic de Barcelona ( Site 0092)
    Barcelona, 08036, Spain
    Recruiting
    • Study Coordinator · Contact34 932275402
  • Hospital Universitario Quiron Madrid ( Site 0091)
    Madrid, 28223, Spain
    Recruiting
    • Study Coordinator · Contact+34914521987
  • Changhua Christian Hospital ( Site 0181)
    Changhua, 50006, Taiwan
    Recruiting
    • Study Coordinator · Contact+886983901629
  • Taipei Medical University Hospital ( Site 0180)
    Taipei, 110, Taiwan
    Recruiting
    • Study Coordinator · Contact+886227372181x7810
  • Chang Gung Medical Foundation-Linkou Branch ( Site 0182)
    Taoyuan, 33305, Taiwan
    Recruiting
    • Study Coordinator · Contact+886975368109
  • Baskent University Dr. Turgut Noyan Research and Training Center ( Site 0141)
    Adana, 01250, Turkey (Türkiye)
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Hacettepe Universite Hastaneleri ( Site 0140)
    Ankara, 06410, Turkey (Türkiye)
    Recruiting
    • Study Coordinator · Contact00903123054330
  • Ankara Bilkent Şehir Hastanesi ( Site 0142)
    Ankara, 06530, Turkey (Türkiye)
    Recruiting
    • Study Coordinator · Contact00905323064615
  • CNE CC of Oncology Hematol ( Site 0130)
    Cherkasy, Cherkasy Oblast 18009, Ukraine
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Municipal Enterprise "Bukovinian сlinical oncology сenter" ( Site 0136)
    Chernivtsi, Chernivetska Oblast 58013, Ukraine
    Recruiting
    • Study Coordinator · Contact0443344770
  • CNCE Precarpathian Clinical Oncologic Center ( Site 0131)
    Ivano-Frankivsk, Ivano-Frankivsk Oblast 76018, Ukraine
    Recruiting
    • Study Coordinator · Contact380978411455
  • VISION PARTNER Medical Centre ( Site 0134)
    Kyiv, Kyivska Oblast 03022, Ukraine
    Completed

    Not enrolling at this site — choose another above.

  • Communal Noncommercial Enterprise "Podillia Regional Oncology Center Of Vinnytsia Regional Council" ( Site 0133)
    Vinnytsia, Vinnytsia Oblast 21029, Ukraine
    Recruiting
    • Study Coordinator · Contact380953105783
  • Shalimov Institute of Surgery and Transplantation ( Site 0135)
    Kyiv, 03126, Ukraine
    Recruiting
    • Study Coordinator · Contact0444081800
08

References and documents

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

09

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Mar 2032, 83 months after the start.

Of 317 industry-sponsored phase 2 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 37 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 59. This study's planned 83 months is above that.

Counting every sponsor, half of 1,047 studies reached it within 48 months; a quarter within 30 and three quarters within 76.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 11, 2024
First posted
Dec 13, 2024
StartActual
Mar 30, 2025
Primary completionEst.
Mar 12, 2032
CompletionEst.
Mar 12, 2032
Last update
Oct 16, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
3 sites added, 3 sites removed. 2 sites changed recruiting status (1 now active, not recruiting, 1 now completed)
Show 2 sites
  • Wielkopolskie Centrum Pulmonologii i Torakochirurgii-Oddzial Onkologii Klinicznej z Pododdzialem Dz ( Site 0153) · Poznan, PolandRecruiting→Active, not recruiting
  • VISION PARTNER Medical Centre ( Site 0134) · Kyiv, UkraineActive, not recruiting→Completed
Show 3 added (1 Chile, 1 Hungary, 1 Spain)
  • Fundación Arturo López Pérez ( Site 0161) · Santiago, Chile
  • Jasz-Nagykun-Szolnok Varmegyei Hetenyi Geza Korhaz-Rendelointezet ( Site 0061) · Szolnok, Hungary
  • Hospital Clinic de Barcelona ( Site 0092) · Barcelona, Spain
Show 3 removed
  • FALP ( Site 0161) · Santiago, Chile
  • Jasz-Nagykun-Szolnok Megyei Hetenyi Gyula Korhaz-Rendelointezet ( Site 0061) · Szolnok, Hungary
  • HOSPITAL CLÍNIC DE BARCELONA ( Site 0092) · Barcelona, Spain
across 2 updates, Oct 7, 2026 – Oct 16, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • Wielkopolskie Centrum Pulmonologii i Torakochirurgii-Oddzial Onkologii Klinicznej z Pododdzialem Dz ( Site 0153) · Poznan, PolandContact removed •••4242
Oct 7, 2026
Show all 2 updates
  1. Oct 16, 2026
    1 site added, 1 site removed
    Show site
    • Hospital Clinic de Barcelona ( Site 0092) · Barcelona, Spain
    Show 1 removed
    • HOSPITAL CLÍNIC DE BARCELONA ( Site 0092) · Barcelona, Spain
  2. Oct 7, 2026
    2 sites added, 2 sites removed. 2 sites changed recruiting status (1 now active, not recruiting, 1 now completed)
    Show 2 sites
    • Wielkopolskie Centrum Pulmonologii i Torakochirurgii-Oddzial Onkologii Klinicznej z Pododdzialem Dz ( Site 0153) · Poznan, PolandRecruiting→Active, not recruiting
    • VISION PARTNER Medical Centre ( Site 0134) · Kyiv, UkraineActive, not recruiting→Completed
    Show 2 added (1 Chile, 1 Hungary)
    • Fundación Arturo López Pérez ( Site 0161) · Santiago, Chile
    • Jasz-Nagykun-Szolnok Varmegyei Hetenyi Geza Korhaz-Rendelointezet ( Site 0061) · Szolnok, Hungary
    Show 2 removed
    • FALP ( Site 0161) · Santiago, Chile
    • Jasz-Nagykun-Szolnok Megyei Hetenyi Gyula Korhaz-Rendelointezet ( Site 0061) · Szolnok, Hungary
    Site contacts Changed at 1 site. See the sites
    Show the site
    • Wielkopolskie Centrum Pulmonologii i Torakochirurgii-Oddzial Onkologii Klinicznej z Pododdzialem Dz ( Site 0153) · Poznan, PolandContact removed •••4242
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06731907
Collaborators
Daiichi Sankyo
Responsible party
Sponsor
First posted
Dec 13, 2024
Start date
Mar 30, 2025
Primary completion
Mar 12, 2032 (estimated)
Completion
Mar 12, 2032 (estimated)
Last update
Oct 16, 2026

Study contacts

Toll Free Number
Contact
Trialsites@msd.com
1-888-577-8839
Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Patritumab deruxtecan

Start the discussion